In March 2018, Mallinckrodt announced the first honorees of the company’s Advancing Extracorporeal Photopheresis (ECP) Immunomodulation Investigator Award – investigator Dr. Nick Matthews and co-investigator Dr. Arun Alfred of the Department of Haematology at Rotherham NHS Foundation Trust in the United Kingdom.
Mallinckrodt developed the Investigator Award to mark 30 years of its pioneering THERAKOS ECP ImmunomodulationTM. The honour reflects the company’s ongoing commitment to the science of immunomodulation through ECP and its therapeutic applications.
The announcement was made at the THERAKOS ECP ImmunomodulationTM symposium during the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Lisbon, Portugal. The award recognises individuals and institutions whose remarkable research contributes to the advancement of knowledge in this area of medicine.
The honorees’ proposal seeks to establish whether immunomodulation achieved through extracorporeal photopheresis (ECP) used in treatments of chronic graft-versus-host disease (GvHD) occurs through mediation of in vivo macrophage activation. Along with the 2018 Investigator Award, the Department of Haematology at Rotherham NHS Foundation Trust will receive an educational grant of €50,000 to support this research.